ETIOPATHOGENESIS OF GASTROINTESTINAL DISEASES

ISSN: 2582-4686 SJIF 2021-3.261,SJIF 20222.889, 2024-6.875 ResearchBib IF: 9.948 / 2024 VOLUME-5, ISSUE-12 251 ETIOPATHOGENESIS OF GASTROINTESTINAL DISEASES Numonova Guzaloy Davronbek kizi Assistant of the Department of Clinical Pharmacology and Medical Biotechnology, ASMI Abstract. The article provides a comprehensive analysis of the etiopathogenesis of gastrointestinal diseases, emphasizing the complex interplay between genetic predisposition, environmental influences, microbiome dysbiosis, immune dysregulation, epithelial barrier damage and neurogastroenterological mechanisms. Modern research shows that GI disorders are not caused by a single factor but emerge from multilayered biological and behavioral interactions. Special attention is given to the role of Helicobacter pylori, dietary imbalance, chronic stress, immunological reactivity and structural abnormalities in triggering pathological processes. The review highlights current scientific perspectives and underscores the importance of integrating molecular, microbial and clinical data to improve diagnostic and therapeutic approaches. Kеywоrds: gastrointestinal diseases, etiopathogenesis, microbiome, inflammation, epithelial barrier, immune system, motility disorders. INTRОDUСTIОN Gastrointestinal diseases represent one of the most widespread and clinically significant groups of disorders in modern medicine. Their etiopathogenesis is highly complex, involving a dynamic interplay between genetic predisposition, environmental triggers, microbial communities, immune mechanisms and social-behavioral factors. Because the gastrointestinal tract performs not only digestion and absorption but also endocrine, immune, and neuroregulatory functions, disturbances at any of these levels can provoke far-reaching pathological changes. Over the past decades, progress in molecular biology, microbiome research, immunology and clinical gastroenterology has allowed scholars to re-evaluate traditional concepts and uncover new mechanistic pathways underlying GI pathology. This article provides a comprehensive examination of key etiological factors and pathogenetic mechanisms that drive gastrointestinal diseases, highlighting their interconnections and biological significance [1]. MАTЕRIАLS АND MЕTHОDS Genetic predisposition plays an essential role in several gastrointestinal disorders, particularly inflammatory bowel diseases (IBD), celiac disease, hereditary colorectal cancers, pancreatic diseases and functional motility disorders. Genome-wide association studies have identified numerous susceptibility loci, including NOD2, IL23R, ATG16L1 and MUC19, which modify immune responses, epithelial barrier integrity and autophagy pathways. The interplay of these genes with environmental triggers such as infections, diet and microbiome dysbiosis determines individual vulnerability. In celiac disease, for instance, HLA-DQ2 and HLA-DQ8 haplotypes provide the basis for gluten antigen presentation, making the adaptive immune system hypersensitive to gliadin peptides. Likewise, hereditary GI cancers often involve mutations in APC, MLH1, BRCA1, STK11 and others, which disrupt genomic stability and cell-cycle regulation. These genetic influences do not act in isolation: they shape the host’s immune and metabolic landscape, creating a permissive environment in which further pathological events unfold [2]. ISSN: 2582-4686 SJIF 2021-3.261,SJIF 20222.889, 2024-6.875 ResearchBib IF: 9.948 / 2024 VOLUME-5, ISSUE-12 252 RЕSULTS АND DISСUSSIОN Environmental exposures are powerful modulators of gastrointestinal health. Dietary imbalance, alcohol abuse, smoking, chronic stress, sedentary lifestyle, and exposure to toxins significantly increase the risk of various GI disorders. Diets rich in saturated fats, refined sugars and processed foods promote oxidative stress, low-grade inflammation, lipid peroxidation and microbiome disruption. By contrast, poor fiber intake impairs short-chain fatty acid (SCFA) production, leading to epithelial atrophy and reduced mucosal immunity. Alcohol directly damages hepatocytes and gastric mucosa, enhances gastric acid secretion, disrupts tight junctions, and sensitizes the mucosa to Helicobacter pylori colonization. Cigarette smoking remains a critical risk factor for peptic ulcer disease, Crohn’s disease flare-ups, esophageal reflux, and malignancy. Stress-related neuroendocrine alterations — primarily hyperactivation of the hypothalamic–pituitary–adrenal axis — impair mucosal healing, slow motility, and increase visceral hypersensitivity. Thus, environmental factors often serve as the initiating or exacerbating triggers for underlying biological vulnerabilities. The intestinal microbiome is now recognized as a central determinant in the etiopathogenesis of GI diseases. A healthy microbiota ensures nutrient metabolism, immune regulation, colonization resistance, mucosal integrity and neurochemical balance. Dysbiosis — a shift in microbial diversity, ratio or metabolic function — can drive inflammation, metabolic disturbances and mucosal barrier breakdown. Reduced populations of Bifidobacteria and Lactobacillus, combined with overgrowth of Clostridioides difficile, Escherichia coli, Klebsiella or other pathobionts, lead to toxic metabolite production, epithelial apoptosis and impaired antimicrobial peptide secretion [3]. Helicobacter pylori remains the most thoroughly studied GI pathogen, responsible for chronic gastritis, peptic ulcer disease, gastric adenocarcinoma and MALT lymphoma. Through virulence factors such as CagA, VacA and urease, H. pylori interferes with epithelial signaling, provokes neutrophil infiltration, induces oxidative stress and drives DNA damage. Viral pathogens, including norovirus, rotavirus and adenovirus, disrupt enterocytes and cause widespread gastroenteritis. Intestinal parasites, such as Giardia lamblia and Entamoeba histolytica, further act as etiological agents by damaging mucosa, altering absorption and triggering chronic inflammation. Microbiome dysbiosis is therefore both a cause and consequence of pathogenesis. The GI tract is a major immunological organ, and immune dysregulation is central to the development of disorders ranging from IBD to autoimmune gastritis and eosinophilic gastrointestinal diseases. An imbalance between pro-inflammatory and anti-inflammatory cytokines — particularly TNF-α, IL-1β, IL-6 and IL-17 versus IL-10 and TGF-β — leads to persistent mucosal inflammation, epithelial destruction and ulceration. In Crohn’s disease, defective innate immunity and impaired bacterial clearance drive granuloma formation and transmural inflammation. Ulcerative colitis, on the other hand, reflects aberrant mucosal immunity dominated by Th2-type responses and epithelial barrier compromise. Autoimmune mechanisms underlie conditions such as celiac disease, autoimmune hepatitis and pernicious anemia, where loss of self-tolerance triggers tissue-specific destruction. Chronic inflammation itself becomes a pathogenetic factor, promoting fibrosis, dysplasia and malignant transformation. The gastrointestinal epithelium serves as a crucial defensive barrier that regulates nutrient absorption while preventing the entry of harmful antigens, toxins and microbes. When this barrier is compromised — due to tight junction disruption, mucin depletion, epithelial injury or altered permeability — pathological processes are set into motion. Increased intestinal permeability (“leaky ISSN: 2582-4686 SJIF 2021-3.261,SJIF 20222.889, 2024-6.875 ResearchBib IF: 9.948 / 2024 VOLUME-5, ISSUE-12 253 gut”) allows luminal antigens to enter the submucosal space, activating immune cascades and sustaining inflammation. Such barrier dysfunction is implicated in conditions like celiac disease, irritable bowel syndrome, non-alcoholic fatty liver disease and various food intolerances. Oxidative stress, microbial proteases, inflammatory cytokines and dietary toxins all contribute to epithelial injury. The cycle becomes self-perpetuating as inflammation further weakens barrier integrity [4]. The enteric nervous system (ENS), often referred to as the “second brain,” regulates motility, secretion, blood flow and sensory perception. Disruptions in ENS function contribute to numerous GI disorders, including gastroparesis, achalasia, intestinal pseudo-obstruction and irritable bowel syndrome. Neurotransmitter imbalances — particularly involving serotonin (5-HT), nitric oxide and acetylcholine — alter visceral sensitivity, peristalsis and sphincter control. Stress-mediated activation of the sympathetic nervous system leads to dysmotility and abdominal pain. Neuropathic processes, such as diabetic neuropathy, Parkinson’s disease and post-infectious neuroinflammation, further compromise neural regulation of the GI tract. Thus, neuro-gastroenterological mechanisms are an essential component of etiopathogenesis. Structural abnormalities such as diverticula, hernias, strictures, tumors, adhesions and congenital malformations (e.g., malrotation, Meckel’s diverticulum) directly disrupt GI continuity and function. Mechanical obstruction leads to stasis, bacterial overgrowth, ischemia and necrosis if not treated promptly. Chronic structural alterations, such as those observed in gastroesophageal reflux disease (lower esophageal sphincter incompetence), gallstone formation or chronic pancreatitis, create conditions that perpetuate inflammation and fibrosis. These changes represent both etiological triggers and long-term consequences of pathological processes. Modern research increasingly views the etiopathogenesis of gastrointestinal (GI) diseases as a multilayered, dynamic, and interdependent set of biological events rather than a linear cause-andeffect chain. The GI tract is now recognized as a complex immuno-neuro-endocrine system in which epithelial integrity, gut microbiota, mucosal immunity, neural signaling, and metabolic homeostasis function as a unified regulatory network. Disruption of any one of these components can initiate pathological cascades that progress into chronic disease states. One of the central mechanisms in the development of many GI disorders is epithelial barrier dysfunction. Tight junction proteins such as claudins, occludin, and zonula occludens (ZO-1) can be altered by inflammatory mediators, oxidative stress, nutritional deficiencies, or pathogenic microorganisms. Increased paracellular permeability permits translocation of bacterial products, including endotoxins and lipopolysaccharides, into the lamina propria. This provokes exaggerated immune responses, leading to persistent mucosal inflammation as seen in inflammatory bowel diseases and chronic gastritis. The inability of the barrier to restore its original configuration contributes to recurrent disease episodes. СОNСLUSIОN The etiopathogenesis of gastrointestinal diseases involves a multifactorial network of biological, environmental, immunological and behavioral determinants. No single factor acts independently; rather, disease emerges from the convergence of genetic susceptibility, microbial imbalance, immune dysfunction, barrier compromise, neuromuscular abnormalities and lifestyle influences. Understanding these interconnected mechanisms is essential for developing targeted diagnostic, preventive and therapeutic strategies. As research continues to unravel deeper molecular pathways — ISSN: 2582-4686 SJIF 2021-3.261,SJIF 20222.889, 2024-6.875 ResearchBib IF: 9.948 / 2024 VOLUME-5, ISSUE-12 254 especially within the microbiome-immune-neural axis — the potential for personalized medicine in gastroenterology will grow, offering more effective interventions and improved patient outcomes. RЕFЕRЕNСЕS 1. Podolsky D.K. Inflammatory bowel disease. — N. Engl. J. Med., 2002. — Vol. 347, No. 6. — P. 417–429. 2. Turnbaugh P.J., Ley R.E., Hamady M. et al. The human microbiome project. — Nature, 2007. — Vol. 449. — P. 804–810. 3. Kusters J.G., van Vliet A.H.M., Kuipers E.J. Pathogenesis of Helicobacter pylori. — Clin. Microbiol. Rev., 2006. — Vol. 19, No. 3. — P. 449–490. 4. Fasano A. Zonulin and its regulation of intestinal barrier function. — Physiol. Rev., 2011. — Vol. 91, No. 1. — P. 151–175. 5. Camilleri M. Gastrointestinal motility disorders. — N. Engl. J. Med., 2021. — Vol. 384. — P. 2381–2391.